Dhillon PK, Mathur P, Nandakumar A et al (2018) The burden of cancers and their variations across the states of India: the global burden of disease. Lancet Oncol 19:1289–1306
Article
Google Scholar
Malvia S, Appalaraju B, Uma S et al (2017) Epidemiology of breast cancer in Indian women. Asia-Pacific J Clin Oncol 13:289–295
Article
Google Scholar
Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML et al (2010) The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Pub Health 21(5):573–577
Article
Google Scholar
Sharma R (2019) Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016. Breast Cancer doi.org/10.1007/s12282-018-00941-4
Wickerham LD, O’Conell MJ, Costantino JP et al (2008) The half century of clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Seminal Oncol 35(5):522–529
Article
Google Scholar
Schmidt M (2014) Chemotherapy in early breast cancer: when, how and which one? Breast Care 9:154–160
Article
Google Scholar
Furquhar C, Majoribanks J, A Lethaby A et al (2016) High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database of Systematic Reviews DOI: https://doi.org/10.1002/14651858.CD003139.pub3
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121
CAS
Article
Google Scholar
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826
CAS
Article
Google Scholar
Van De Vijver MJ, He YD, Van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl J Med 347(25): 1999–2009
Nielsen TO, Parker JS, Leung S et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer. Clin Cancer Res 16(21):5222–5232
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M, EP Investigators (2011) A new molecular predictor of distant recurrence in ER positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18):6012–6020
CAS
Article
Google Scholar
Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O (2011) Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104(11):1762–1769
CAS
Article
Google Scholar
Ramkumar C, Buturovic L, Malpani S et al (2018) Development of a novel proteomic risk-classifier for prognostication of patients with early-stage hormone receptor–positive breast cancer. Biomark Insights 13:1177271918789100
Article
Google Scholar
Bakre MM, Ramkumar C, Attuluri AK et al (2019) Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Med doi. https://doi.org/10.1002/cam4.2049
Attuluri AK, Prakash VSC, Gunda A et al (2019) Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients. BMC Cancer 19(1):249
Article
Google Scholar
Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen’s International Expert consensus on the primary therapy of early breast cancer 2013. Annals Oncol 24:2206–2223
CAS
Article
Google Scholar
Cardoso F, van’t Veer LJ, Bogearts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. New Eng J Med 25;375(8):717-29
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12(1):R1
Article
Google Scholar
Haybittle JL, Blamey RW, Elston CW et al., A prognostic index in primary breast cancer. (1982) Br J Cancer 45(3):361–366
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991
CAS
Article
Google Scholar
Raina V, Bhutani M, Bedi R et al (2005) Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Ind J Cancer 42(1): 36-41. Int Surg J 4(3): 913–915
Agarwal G, Ramakant P (2008) Breast cancer care in India: current scenario and challenges for the future. Breast Care 3:21–27
Article
Google Scholar
Almas A (2017) Clinical profile of carcinoma breast cases at a tertiary care hospital. Int J Surg 4(3):913–915
Article
Google Scholar
Lambertini M, Pinto AC, Ameye L et al (2016) The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British J of Cancer 115:1471–1478
Article
Google Scholar
Engelhardt EG, Garvelink MM, de Haes JH et al (2014) Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol 20 32(3):238–250
Article
Google Scholar
Maishman T, Copson E, Stanton L, Gerty S, Dicks E, Durcan L et al. (2015) An evaluation of the prognostic model PREDICT using the POSH cohort of women aged 40 years at breast cancer diagnosis. Br J Cancer112(6):983-991
Sivasubramaniam PG, Zhang B, Zhang Q et al (2015) Breast cancer disparities: a multicenter comparison of tumor diagnosis, characteristics, and surgical treatment in China and the U.S. The Oncol 20:1044–1050
Article
Google Scholar
Kwang A, Cheung P, Chan S et al (2008) Breast cancer in Chinese women younger than age 40: are they different from their solder counterparts? World J Surg 32(12):2554–2561
Article
Google Scholar
Lo SS, Mumby PB, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection 10:1671-1676
Curtit E, Vanettzel J, Darmon J et al (2019) Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: real-life utilization and decision impact in French clinical practice. BMC Cancer:39–45
Holt S, Bartelli G, Humphreys I et al (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK B J Cancer 108, 2250–2258
Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C (2013) The EndoPredict gene-expression assay in clinical practice - performance and impact on clinical decisions. PLoS One 8(6):e68252
Article
Google Scholar
Kuijer A, Straver M, Dekker B et al (2017) Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor–positive early breast cancer: results of a prospective cohort study. J Clin Oncol 24:2814–2819
Article
Google Scholar